Studies have found that hs-CRP can chemotactic monocytes at the site of vascular sclerosis, induce monocytes to produce tissue factor, activate complement, induce endothelial cells to produce adhesion factors, impair endothelial function, and accelerate the progression of arteriosclerosis. This evidence concerns the gene F3 and arteriosclerosis disorder.